Work

Autologous, allogeneic, in vivo CAR for autoimmune diseases

Year: 2025

Type: article

Abstract: Chimeric antigen receptor (CAR)-based therapies are emerging for autoimmune diseases (ADs). Early-phase clinical studies in systemic lupus erythematosus (SLE) show encouraging results using autologous, allogeneic, and in vivo CAR T-cell (CAR-T) strategies. This forum compares these three strategies, highlighting clinical design, safety, and efficacy, and explores the translational challenges of in vivo CAR engineering in ADs.

Source: Trends in Pharmacological Sciences

DOI: 10.1016/j.tips.2025.11.001

Authors: Yan-Ruide Li, Lili Yang

Institutions: University of California, Los Angeles, Parker Institute for Cancer Immunotherapy, UCLA Jonsson Comprehensive Cancer Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $7,030